secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001453687-22-000136
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Selecta Q3 net loss narrows to $7.9M; cash runway to mid-2024
-------------------------------------------------------------

- Net loss of $7.9M ($0.05 per share) vs $17.9M loss in Q3 2021; collaboration revenue $20.7M.
- Cash, equivalents & securities total $148.0M as of Sep 30, 2022; expected runway into mid-2024.
- Received $10M milestone from Sobi for DISSOLVE II enrollment and $6M from Sarepta for DMD/LGMD.
- Topline data from Phase 3 DISSOLVE (SEL-212 for chronic gout) expected in Q1 2023.
- Phase 1 trial of SEL-302 (MMA gene therapy) on track to begin Q4 2022; IL-2 and IgA protease candidates by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368722000136/0001453687-22-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368722000136/selb-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001453687-22-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer